ClinicalTrials.gg
RecruitingNCT07036601Updated Jun 25, 2025

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

A Phase 2 interventional study of THDBH120 injection and Placebo of THDBH120 injection in Overweight or Obese, sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Tonghua Dongbao Pharmaceutical Co.,Ltd · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jan 2025, registered Jun 2025).
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 330 studies in Overweight with a site in China — 123 open to participants now, 166 under way, 43 of them phase 3. Overweight · China.

Planned enrollment
85th of 296
276 · median 120
Started
2025
with 65 others
Phase 2
37 of 330
11 open now
Primary completion
2026-02
later than 22 of 165 live
Registered
172nd of 330
by date

Among the 330 studies in Overweight with a site in China, this one is the 85th largest by planned enrollment of the 296 interventional ones that give a count, is one of 66 that started in 2025, is one of 37 in phase 2, reaches primary completion later than 22 of the 165 other live ones, and was the 172nd registered.

Overweight

3,613 studies on the registry are indexed under Overweight; 856 are open to participants now.

Browse Overweight studies →

Open to participants now

123 of the 330 studies in Overweight with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 531 Overweight studies recruiting now, 159 (30%) set no upper age limit and 344 (65%) stop at 75 or younger; 63 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 330 studies in Overweight with a site in China, or all of them as a file.
02

Study summary

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

03

Conditions studied

  • Overweight or Obese
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 to 75 years of age, inclusive;
  • Have a ≥ 28 kg/m² or 24 ≤BMI\< 28.0 kg/m² with at least 1 weight-related comorbidity at screening: prediabetes, hypertension, metabolic-associated fatty liver disease, dyslipidemia, weight-bearing joint pain, or obstructive sleep apnea syndrome;
  • Diet and exercise control for at least 3 months before screening visit, and less than 5% self-reported change within the last 3 months.

Exclusion criteria

Exclusion Criteria:

  • History of diabetes;
  • History of obesity attributable to endocrine diseases, monogenic mutations, or drug-induced causes, such as hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, or hypogonadism; or weight gain resulting from increased non-fat mass (e.g., edema);
  • Presence of uncontrolled hypertension at screening: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
  • A 12-lead (ECG) shows any of the following at screening: heart rate \<50 bpm or >100 bpm; prolongation (QT interval corrected by Fridericia's formula: QTc = QT/RR\^0.33; >450 ms for males, >470 ms for females); PR interval >200 ms; presence of long QT syndrome; second- or third-degree atrioventricular block; left bundle branch block; complete right bundle branch block; Wolff-Parkinson-White syndrome; or any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    THDBH120 injection

    Drug: THDBH120 injection

  • Placebo comparator
    Placebo of THDBH120 injection

    Drug: Placebo of THDBH120 injection

Interventions

  • Participants received THDBH120 by subcutaneous injection.

  • DrugPlacebo of THDBH120 injection

    Participants received placebo by subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight

    Time frame: Baseline, Week26

Secondary outcomes

  1. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Time frame: Baseline, Week26

  2. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Time frame: Baseline, Week26

  3. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Time frame: Baseline, Week26

  4. Percentage of Participants Who Achieve ≥20% Body Weight Reduction

    Time frame: Baseline, Week26

  5. Change from baseline in waist circumference after the treatment

    Time frame: Baseline, Week 26

  6. Change from baseline in BMI after the treatment

    Time frame: Baseline, Week 26

  7. Change from baseline in blood pressure after the treatment

    Time frame: Baseline, Week 26

  8. Change from baseline in HbA1c after the treatment

    Time frame: Baseline, Week 26

  9. Change from baseline in total cholesterol after the treatment

    Time frame: Baseline, Week 26

  10. Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)

    Time frame: Week 30

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Feb 2026, 13 months after the start.

Of 102 industry-sponsored phase 2 interventional studies under Overweight, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 16. This study's planned 13 months is close to that.

Counting every sponsor, half of 148 studies reached it within 13 months; a quarter within 8 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2025
First posted
Jun 25, 2025
StartActual
Jan 6, 2025
Primary completionEst.
Feb 13, 2026
CompletionEst.
Mar 11, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07036601
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Responsible party
Sponsor
First posted
Jun 25, 2025
Start date
Jan 6, 2025
Primary completion
Feb 13, 2026 (estimated)
Completion
Mar 11, 2026 (estimated)
Last update
Jun 25, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: THDBH120

Start the discussion